for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Tan Sheet
  [0 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1530-1206
   Published by Informa plc Homepage  [16 journals]
  • Perrigo Weathering Change At Helm As It Navigates Earnings Storm
    • Abstract: The OTC private label giant promotes John Hendrickson from president to CEO after Joseph Papa resigns to take the same post at beleaguered specialty pharma Valeant Pharmaceutical International. A lower earnings forecast combined with the leadership change sent Perrigo's share price down 18.09%.
      PubDate: Tue, 26 Apr 2016 00:00:02 -040
       
  • Antiperspirant Sales Drivers Smell Natural, With Additional Benefits
    • Abstract: The US deodorant/antiperspirant market is shaped by growing demand for natural products and formulas that rely on innovative technologies, say two research firms in separate reports. The US underarm care market is anticipated to reach nearly $3.5bn in revenue by 2019.
      PubDate: Mon, 25 Apr 2016 00:02:00 -040
       
  • Will Ferrell's Latest SPF Makes Waves, Offers New Insight On Sun Dangers
    • Abstract: Former SNL cast member Will Ferrell teamed with a college buddy and founder of charity Cancer for College to create a line of sun-protection products in 2009. Formulated to combat the "evil celestial demon" (the sun), the latest iteration – SPF 30 Super Mega Sexy Hot Tan – is available in a two-pack at the organization's website for $25.
      PubDate: Mon, 25 Apr 2016 00:02:00 -040
       
  • Califf Lowering FDA Drawbridge To Work With External Expertise
    • Abstract: In Pink Sheet's exclusive interview, new commissioner says FDA will tap knowledge beyond its walls, without compromising agency independence.
      PubDate: Mon, 25 Apr 2016 00:02:00 -040
       
  • Califf Says He Won't Need To Fight To Stay
    • Abstract: FDA's new commissioner may be asked to leave agency when new president arrives, but he says it might not come to that.
      PubDate: Mon, 25 Apr 2016 00:01:55 -040
       
  • Weekly Trademark Review April 19, 2016
    • Abstract: OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.
      PubDate: Mon, 25 Apr 2016 00:01:46 -040
       
  • Consumer Health New Products Roundup: Nix Ultra,
           Amway In Nutrition
    • Abstract: Klean BCAA + PEAK launch; Soothease to erase chemo treatment taste; E-hydrate for youth; more news in brief.
      PubDate: Mon, 25 Apr 2016 00:01:15 -040
       
  • Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
    • Abstract: House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.
      PubDate: Mon, 25 Apr 2016 00:01:03 -040
       
  • Private Label Mucinex Outlook Stays Clogged On Court
           Ruling Against Mutual
    • Abstract: A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.
      PubDate: Fri, 22 Apr 2016 00:00:05 -040
       
  • One-Two Punch On Supplements From Former FDA Investigator, Harvard
           Researchers
    • Abstract: Jeff Novitzky, VP of athlete health and performance at Ultimate Fighting Championship, discusses violative supplements at a Dietary Supplement Caucus briefing for lawmakers and congressional staff. Harvard researchers roundly criticize the products' potential health benefits.
      PubDate: Thu, 21 Apr 2016 00:00:02 -040
       
  • PDUFA Clock Ticks For FDA Decision On First OTC Acne Ingredient NDA
    • Abstract: Under PDUFA timelines for supplemental NDAs, FDA has until sometime in June to make a decision on Galderma Labs' application, or to state that it will need more time before announcing its conclusion.
      PubDate: Wed, 20 Apr 2016 00:00:10 -040
       
  • J&J's Analgesic Sales Ease Pain Of Ongoing OTC Turnaround
    • Abstract: CFO Dominic Caruso reaffirms &&J’s commitment to keeping and growing its consumer business as the firm reports its OTC adult analgesic US market share reached 14% while pediatric share was nearly 46%.
      PubDate: Wed, 20 Apr 2016 00:00:03 -040
       
  • FTC Action On 'All Natural' Claims Likely To 'Embolden' Plaintiffs
    • Abstract: Attorneys agree that FTC's announced settlements with personal-care companies for misleading "all-natural" claims likely will not be helpful to class-action defendants making primary-jurisdiction arguments and could actually spur more litigation, similar to trends following FDA warning letters.
      PubDate: Tue, 19 Apr 2016 00:55:01 -040
       
  • NDAC Support For Galderma's Acne Drug OTC Approval Comes With Advice On
           Evaluating Switches
    • Abstract: FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for input on evaluating future NDAs for other switches that would introduce new risks to the OTC space.
      PubDate: Mon, 18 Apr 2016 01:00:00 -040
       
  • 'Migraine Experience' Debuts Excedrin Advertising By
           Glaxo/Novartis JV
    • Abstract: Excedrin Migraine’s multi-channel campaign, the first major promotion for the brand since moving into the Glaxo/Novartis JV, incorporates "augmented reality" technology for a window into the struggles of migraine sufferers.
      PubDate: Mon, 18 Apr 2016 00:05:01 -040
       
  • FDA Consumer Health Product Recalls For April 13
    • Abstract: Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
      PubDate: Mon, 18 Apr 2016 00:01:34 -040
       
  • Weekly Trademark Review April 12, 2016
    • Abstract: OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.
      PubDate: Mon, 18 Apr 2016 00:01:24 -040
       
  • FTC 'All Natural' Claims Crackdown Nets Sunscreen Marketers
    • Abstract: Marketers should ensure they are not misleading consumers with "100% natural" or "all-natural" for products that contain synthetic ingredients, the agency says. FTC is settling with four firms over such claims on skin, hair and sunscreen products and issued a complaint against a fifth.
      PubDate: Mon, 18 Apr 2016 00:01:11 -040
       
  • Industry Roundup: Folic Acid Rule, Acacia Rigidula Recall
    • Abstract: FDA allows folic acid in corn masa flour; more acacia rigidula supplements found; UNPA, NAXA collaborate; and more news in brief.
      PubDate: Mon, 18 Apr 2016 00:01:06 -040
       
  • Acne Drug Switch Study Stirs FDA Doubts About Pregnant Women's
           Self-Selection
    • Abstract: The NDAC met April 15 to make recommendations on Galderma's first-in-class switch proposal for adapalene gel 0.1% indicated for treatment of acne in consumers ages 12 and older. FDA told the committee Galderma's study did not "demonstrate that pregnant or breastfeeding women could adequately self-select to use the product."
      PubDate: Mon, 18 Apr 2016 00:01:00 -040
       
  • Growing Class Action Threat Targets Firms' Website Terms, Conditions
    • Abstract: Lush Cosmetics is among companies facing proposed class actions alleging violations of a New Jersey consumer protection law. Trade groups and legal experts warn the more than 30-year-old statute is being invoked increasingly by plaintiffs to attack the fine print on firms' e-commerce sites.
      PubDate: Mon, 18 Apr 2016 00:00:16 -040
       
  • Optometrists Group Says FDA Should Regulate Online Eye-Test Provider
    • Abstract: Opternative allows consumers to take an eye test via their computer or smartphone, practices the American Optometric Association said could pose a risk to patient safety. The trade group wants FDA to require an approval for the service.
      PubDate: Mon, 18 Apr 2016 00:00:04 -040
       
  • Galderma's Acne Drug Switch Gets Unanimous NDAC Support
    • Abstract: If approved by FDA, the product, to be marketed as Differin Gel, would be the first OTC drug available in the US that contains an ingredient in the retinoid category, adapalene 0.1 gel.
      PubDate: Fri, 15 Apr 2016 18:15:02 -040
       
  • Acne Drug Switch Study Raises FDA Doubts About Pregnant Women's
           Self-Selection
    • Abstract: The Nonprescription Drugs Advisory Committee meets on April 15 to discuss Galderma's first-in-class switch proposal for adapalene gel 0.1% indicated for treatment of acne in consumers ages 12 and older, the traditional indication for OTC acne treatments.
      PubDate: Fri, 15 Apr 2016 00:00:03 -040
       
  • CRN Targets 'Ticket To Play' With Supplement Registry
    • Abstract: CRN says in addition to requiring its members to list their products on an NIH-managed label database, by the end of 2016 it will launch a registry for label and other information about vitamins, supplements, minerals and other nutritionals available in the US.
      PubDate: Wed, 13 Apr 2016 09:35:00 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015